Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of November 5, 2026, AKBA trades at $0.52 with a market cap of $201.12M and a P/E ratio of -7.53. AKBA moved -25.87% today. Year to date, AKBA is -54.24%; over the trailing twelve months it is -66.94%. Its 52-week range spans $0.54 to $4.08. Analyst consensus is strong buy with an average price target of $3.90. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for AKBA shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $0.52 |
| Market Cap | $201.12M |
| P/E Ratio | -7.53 |
| EPS | $-0.12 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.08 |
| 52-Week Low | $0.54 |
| Volume | 229.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $219.06M |
| Net Income | $-29.67M |
| Gross Margin | 79.63% |
5 analysts cover AKBA: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.90.